Sig­ilon fo­cus­es on type 1 di­a­betes, re­duces spend on MPS-1 af­ter let­ting CMO go (cor­rect­ed)

Sig­ilon Ther­a­peu­tics said it de­creased ex­ter­nal spend on a rare lyso­so­mal stor­age dis­or­der as the Bob Langer-found­ed biotech fo­cus­es its cell ther­a­py pipeline on type 1 di­a­betes.

The an­nounce­ment comes af­ter the biotech ter­mi­nat­ed the po­si­tion of its chief med­ical of­fi­cer, May Or­fali, last month. Or­fali re­mains as a con­sul­tant to Sig­ilon. In in­ter­views af­ter pub­li­ca­tion, she and CEO Rogério Vi­val­di said the ter­mi­na­tion was due to the port­fo­lio pri­or­i­ti­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER